Stemcyte India Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 26-06-2024
- Paid Up Capital ₹ 0.98 M
as on 26-06-2024
- Company Age 16 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -1.22%
(FY 2022)
- Profit -103.95%
(FY 2022)
- Ebitda -106.07%
(FY 2022)
- Net Worth -39.93%
(FY 2022)
- Total Assets -17.42%
(FY 2022)
About Stemcyte India Therapeutics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.98 M, as per Ministry of Corporate Affairs (MCA) records.
Chandra Chivukula, Wise Young, and Amitabha Banerjee serve as directors at the Company.
- CIN/LLPIN
U85100GJ2008FTC052859
- Company No.
052859
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
08 Feb 2008
- Date of AGM
11 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Stemcyte India Therapeutics Private Limited offer?
Stemcyte India Therapeutics Private Limited offers a wide range of products and services, including Medical Surgery & Treatment Centres, Medical Facilities.
Who are the key members and board of directors at Stemcyte India Therapeutics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Wise Young  | Director | 27-Mar-2014 | Current |
Amitabha Banerjee  | Director | 08-Dec-2011 | Current |
| Chandra Chivukula | Director | 28-Oct-2021 | Current |
Financial Performance and Corporate Structure Insights of Stemcyte India Therapeutics.
Stemcyte India Therapeutics Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 1.22% decrease. The company also saw a substantial fall in profitability, with a 103.95% decrease in profit. The company's net worth observed a substantial decline by a decrease of 39.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stemcyte India Therapeutics?
In 2023, Stemcyte India Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Gig - Irm Glass Insulators Private LimitedActive 5 years 4 monthsAmitabha Banerjee is a mutual person
Apollo Specialty Hospitals Private LimitedActive 15 years 6 monthsChandra Chivukula is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Stemcyte India Therapeutics?
Unlock and access historical data on people associated with Stemcyte India Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stemcyte India Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stemcyte India Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
